Health Care Heroes award winner: Craig Smith, Second Chance Fundraising
Craig Smith is a 2018 Health Care Heroes award winner in the volunteer category. Here's his story: Dressing up as a giant heart wasn’t what Craig Smith first envisioned when he decided he wanted to give back to the community that supported him after he had a heart transplant. In his early 20s, Smith was d iagnosed with viral cardiomyopathy, a degenerative heart disorder. In 2015, he underwent a successful heart transplant procedure at Allegheny General Hospital. While living in Johnstown, Smith…
We investigated whether atorvastatin can alleviate diabetic cardiomyopathy (DM CMP) by reducing intracellular matrix metalloproteinase-2 (MMP-2) isoform expression.
Systolic heart failure (HF) is a progressive disease characterized by adverse remodeling from ischemia (ischemic cardiomyopathy, ICM) or a multitude of other causes termed non-ischemic cardiomyopathy (NICM). To accurately characterize the myocardial transcriptome in advanced HF using RNA-sequencing (RNAseq) and identify gene signatures that predict HF phenotypes.
Intravenous methamphetamine (IV meth) use in potential heart donors has been of concern due to the possibility of methamphetamine cardiomyopathy and transmission of infections. There is also concern regarding the development of primary graft dysfunction (PGD) and cardiac allograft vasculopathy (CAV) due to possible endothelial cell dysfunction. Therefore, we reviewed our HTx data to identify those donors who primarily used IV meth in the past 6 months prior to organ donation.
Although right ventricular (RV) dysfunction represents an important adverse prognostic factor in non-ischemic dilated cardiomyopathy (NICM), the underlying mechanisms remain poorly defined. We investigated a potential correlation between RV dysfunction and alterations in angiogenesis in this patient cohort.
In nonischemic cardiomyopathy (NICM), CD34+ cell transplantation was shown to improve left ventricular dimensions and function. We sought to investigate the effects of such therapy on functional mitral regurgitation (FMR) in this patient cohort.
Occasionally new onset cardiomyopathy patients (pts) present late, in such advanced disease stage that they cannot tolerate heart failure (HF) drug therapy. We investigated the cardiac recovery (CR) potential following a combination of left ventricular assist device (LVAD) and guideline-directed HF drug therapy in this medication-naive population.
Noncompaction cardiomyopathy (NCC) results as an arrest of the myocardial compaction process in the embryonic period, leading to the impaired formation of the microvasculature. Myocardial perfusion abnormalities have already been described, however, the functional impact in NCC patients remains undefined. We sought to analyze a potential correlation between myocardial ischemia and heart failure progression in patients with NCC.
Transthyretin amyloid cardiomyopathy (ATTR-CM), an underdiagnosed, fatal disease caused by the deposition of transthyretin amyloid fibrils in the heart leading to heart failure, can be hereditary, due to mutations in the transthyretin gene, or wild-type. Tafamidis, a selective transthyretin stabilizer which prevents tetramer dissociation and amyloidogenesis, was recently shown to be an effective treatment for ATTR-CM patients in the international, multicenter, double-blind, placebo-controlled, randomized, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).
In this study, we tested the hypothesis that children and adults with DCM and heart failure (DCM/HF) display different plasma peptide biomarker profiles.
The objective was to identify genetic characteristics associated with earlier onset or severe phenotype.